anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,022,171. Slow-release medicinal tablets. WELLCOME FOUNDATION Ltd. May 31, 1962 [June 15, 1961], No. 21593/61. Heading A5B. A prolonged release medicinal tablet comprises a medicated portion and a non-medicated inert portion which is physiologically acceptable, substantially insoluble, indigestible and unabsorbable in the fluids of the gastro-intestinal tract of man, and substantially impermeable to the medicament, said inert portion covering part but not all of the surface of the medicated portion. Suitable inert materials are sublimed sulphur, bone phosphate, barium sulphate, calcium silicate, aluminium silicate, or a mixture thereof; preferably the inert material is in admixture with a "plastic" such as polyvinyl acetate, a natural resin such as colophony, a wax such as beeswax, paraffin wax or hydrogenated castor oil, or a mixture thereof. The inorganic substances comprise 20- 99 per cent by weight of the inert portion and the "plastic" and wax respectively from 0 to 10% and from 15 to 18% wt. The inert portion is compressed on to a preformed medicated core by a compression coating technique. Not more than 50% of the surface area of the medicated portion is exposed. As shown in Figures I and II, a tablet consists of an inert portion 2 surrounding the medicated portion 1 and is provided with a hole 3 extending into the medicated portion 1.
All treatments will be given in the outpatient setting. A cycle is 21 days. The sequence of infusions on Day 1 will be IV paclitaxel (135 mg/m2), then IV bevacizumab (15 mg/kg, beginning Cycle 2). On Day 2 patients will receive IP cisplatin (75 mg/m2). Patients will be given twice-daily treatment with oral olaparib in cycles 1-6 for 7 consecutive days, starting on Day 2 (Days 2-8). IP paclitaxel (60 mg/m2) will be given on Day 8. Sequential cohorts of 3 patients will receive escalating doses of olaparib (50mg BID, 100mg BID, 200mg BID).
Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points. Before the procedure, the femoral artery was visualized with a linear ultrasound probe to prevent arterial injury by entering 2 cm lateral to the femoral artery. Following this, a mixture of 2.5 cc of 0.05% bupivacaine and 2.5 cc of 6% phenol was applied, and a lesion was created for 90 seconds at 80°.
This study was conducted in pgimer. Patients presenting with fever and thrombocytopenia in emergency medical opd / medicine opd were screened and all dengue serology positive patients were evaluated for enrolment into the study. We had proposed to enroll 30 patients with diagnosed dengue haemorrhagic fever. the diagnosis of the dengue fever was based upon the clinical history ,general physical examination and the lab tests : thrombocytopenia ( platelet count ≤ 20,000 ) ,and a positive dengue serology.

STUDY DESIGN : It was an open label inteventional study . one group of 15 patients ( intervention group ) received platelet support along with injection anti-d in a dose of 50 µg/kg (250IU/kg) intravenously while the other group of 15 ( control group) received platelet support only . a base line platelet count of all the participant of both the study groups was taken and then the level of platelets at 12 , 24 , 36 , and 48hr post treatment initiation was noted. The patients were followed till the time of discharge .
BACKGROUND: Mesenchymal Stromal Cells (MSCs) are the preferred candidates for therapeutics as they possess multi-directional differentiation potential, exhibit potent immunomodulatory activity, are anti-inflammatory, and can function like antimicrobials. These capabilities have therefore encouraged scientists to undertake numerous preclinical as well as a few clinical trials to access the translational potential of MSCs in disease therapeutics. In spite of these efforts, the efficacy of MSCs has not been consistent-as is reflected in the large variation in the values of outcome measures like survival rates. Survival rate is a resultant of complex cascading interactions that not only depends upon upstream experimental factors like dosage, time of infusion, type of transplant, etc.; but is also dictated, post-infusion, by intrinsic host specific attributes like inflammatory microniche including proinflammatory cytokines and alarmins released by the damaged host cells. These complex interdependencies make a researcher's task of designing MSC transfusion experiments challenging.
METHODS: In order to identify the rules and associated attributes that influence the final outcome (survival rates) of MSC transfusion experiments, we decided to apply machine learning techniques on manually curated data collected from available literature. As sepsis is a multi-faceted condition that involves highly dysregulated immune response, inflammatory environment and microbial invasion, sepsis can be an efficient model to verify the therapeutic effects of MSCs. We therefore decided to implement rule-based classification models on data obtained from studies involving interventions of MSCs in sepsis preclinical models.
RESULTS: The rules from the generated graph models indicated that survival rates, post-MSC-infusion, are influenced by factors like source, dosage, time of infusion, pre-Interleukin-6 (IL-6)/ Tumour Necrosis Factor- alpha (TNF-α levels, etc. CONCLUSION: This approach provides important information for optimization of MSCs based treatment strategies that may help the researchers design their experiments.
NEW MATERIAL:The fat-soluble elastin peptide of formual (R is aliphatic carboxylic acid residue; R' is alkyl; n is 2-300). USE:Cosmetic. It is soluble in an oil base and can be compounded to an oil-based cosmetic. It is a pale yellow to pale yellowish brown crystal hardly soluble or insoluble in water. PROCESS:The ligament or vascular wall constituting the dermatic tissue of mammals is treated with an acid or an alkali, and then extracted e.g. by boiling (hot) oxalic acid treatment, hydrolysis with an alkali containing alcohol, digestion with elastic, etc. The obtained elastin peptide solution is mixed with a dilute alkali solution, added dropwise with a carboxylic acid halogenide, and stirred. The product is filtered, washed, and crystallized to obtain the compound of formula.
PROBLEM TO BE SOLVED: To obtain an ophthalmic composition capable of enhancing a refreshing feeling and persistence without increasing the irritation to eyes. SOLUTION: This ophthalmic composition is characterized as comprising a menthol glycoside represented by the general formula (1) (wherein, R denotes a residue of monosaccharide or oligosaccharides) as a refreshing agent. Menthol glycosides in which the constituent saccharide residue is a residue of monosaccharides, e.g. glucose, galactose, mannose, N-acetylgucosamine, N- acetylgalactosamine, ribose, arabinose, xylose or rhamnose and a residue of disaccharides, e.g. maltose, lactose, isomaltose, cellobiose or gentiobiose are cited as the menthol glycoside. Among them, in particular, the menthol glycoside in which the saccharide residue is maltose is excellent in persistence and preferable. Although two kinds of αand β type isomers (anomers) are persent in the glycoside, either one or a mixture of both may be used.
Every year, thousands of people in Germany succumb to severe injuries. But what causes the death of these patients? In addition to the trauma, pre-traumatic health status, age, and other influencing factors play a role in the outcome after trauma. This study aims to answer the question of what causes the death of a severely injured patient.For this publication, in addition to previously published results, we examined current data from patients in German hospitals from the years 2015-2022 (8 years) documented in the TraumaRegister DGU®. The feature "Presumed Cause of Death", introduced in 2015, was considered. Patients transferred out early (< 48 h) as well as patients with minor injuries were excluded from this analysis.The number of fatalities decreases over time and does not correspond to a traditionally postulated tri-modal mortality distribution. Instead, over time, the distribution of causes of death shows significant variation. In over half of the cases (54%), traumatic brain injury (TBI) was the presumed cause of death, followed by organ failure (24%) and haemorrhage (9%). TBI dominates, especially in the first week, haemorrhage in the first 24 h, and organ failure as a cause steadily increases over time.In summary, it can be observed that the risk of death due to trauma-related consequences is highest in the first minutes, hours, and days, decreasing steadily over time. Particularly, the extent of injuries, head injuries, and significant blood loss are early risk factors.
The same anti-viral, anti-inflammatory, and anti-coagulation treatment criteria are applied to the treatment group. If the primary endpoint will be not reached by day 14 of randomization, IVIG can be given at a dose of 1,000 mg/kg based on clinicians' discretion.
Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
Participants were rigorously evaluated by the same endocrine doctor and podiatrist at baseline (Session 1) and at the end of the study after weight loss intervention (Session 2), when each participant had lost between 11-12% of its corporal weight. Therefore, we obtained 2 weight related with the two sessions: Session 1 - Weight 1; Session 2 - Weight 2.
People with dementia (PWD) often lose weight and suffer subsequent health issues: the goal of this intervention is to improve or maintain weight of a PWD, and to improve or maintain food intake. A train-the-trainer intervention is used with volunteers in Respite Care Centers who partner with family caregivers of PWD. Designed to be personalized to the PWD and focusing on his/her existing strengths and compensating for his/her deficits in mealtime management, sessions occur initially (1 hr) and every month (\~30 mins) to reinforce key areas of behavioral or environmental change. Samsung tablets are used initially and then monthly (x5) to record mealtimes in the home, and are reviewed by the volunteer with the family member at the monthly session to discuss areas where changes could be made.
Patients will receive single doses of modafinil (200 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
PURPOSE: A yeast cell automatic counting method of a yeast culture solution using a pc camera and a general optical microscope are provided to automatically count the yeast cell of a yeast culture solution using an economic system comprising a PC camera and a general optical microscope. CONSTITUTION: A system acquires an image. The system divides the image into 48 blocks and produces the brightness value average value of each block. The system produces the binarization threshold which is proportional to the brightness value average value. The system converts a color image into a gray scale image. The system converts the gray scale image into a white/black image using image binarization based on the binarization threshold. The system automatically counts yeast cells by labeling of the image. [Reference numerals] (AA) Acquire an image; (BB) Convert the RGB color space of an original image into an HSV color space; (CC) Divide the image into 48 blocks and produce the average brightness value of each block; (DD) Produce the binarization threshold which is proportional to the average brightness value of each block; (EE) Convert a color image into a gray scale image; (FF) Convert the gray scale image into a white/black image using image binarization based on the binarization threshold; (GG) Automatically count yeast cells by labeling
In adults, there is growing evidence that early TRE is more effective in improving metabolic outcomes than other forms of TRE, however it is unclear whether adolescents will be able to adhere to such recommendations. Hence, in the present study we propose a 24-week, 2-arm, parallel randomized pilot trial in 100 adolescents (age 13-18 years, all gender expressions, anticipate 65% Latino) with obesity, to test the preliminary efficacy of early vs. late TRE on glycemic profiles, weight loss, and body composition. We hypothesize that, among adolescents who can adhere to the meal timing recommendations, early TRE will result in greater improvement in metabolic endpoints than late TRE. We will test the hypothesis with 3 specific aims: Aim 1: Test the effect of early vs. late TRE on glycemic profiles and β-cell function. Aim 2: Test the effect of early vs. late TRE on obesity and body composition, and cardiometabolic risk factors. Aim 3: Test the effect of early vs. late TRE on exploratory outcomes including sleep, physical activity, and dietary intake to explore how meal timing may influence occurrence, timing, and distribution of sleep and movement as well as dietary intake and caloric distribution. This study is the first study evaluating the effectiveness of early vs. late TRE in adolescents with obesity at risk for diabetes.
A device and method are presented wherein a common drug (304) for a particular treatment is given to the patient in an inactive form. The drug (304) can be administered systemically or topically. The activity of the drug (304) is regulated by photoactivatible fulleren molecules (300, 302) to which the drug (304) is complexed. When the drug (304) is encapsulated in or attached to the photoactivatible fullerene molecule (300, 302, 400, 402), it is inactive. However, when the inactive drug (304) complex is subjected to selective irradiation, the complex is broken and the drug (304) is released in an active form. Treatment can be administered over a wide range of body areas, both internally and externally. The selectivity allows the drug (304) in non-treatment areas to remain inactive, and then be removed or passed harmlessly from the body. The present invention facilitates drug treatment administration by allowing very specific treatment while minimizing the side effects.
FIELD: medicine, pharmacology. SUBSTANCE: agent has low-molecular component prepared from protein-containing raw by extraction with organic solvents followed by substance drying and its dissolving in 60-90-% alcohol, ionized selenium organic salt and additionally - organic structural carbohydrates, phospholipids, phospholipocarbo- -hydrates, carotene-carbohydrates and cyanocarbohydrates. Mixture of these substances is placed in electromagnetic sinusoidal high-frequency field and kept at 20-30 MHz for 5 min. One ml of complex of immunocorrecting agent has 20-30 mg of substance and 6 mcg of selenium in the mole ratio of organic structures to proteoselenium 1:5. Invention provides preparing medicinal agent without adverse effects, it induces systemic curative effect based on normalization of energetic processes in immune system. EFFECT: enhanced effectiveness of agent. 18 cl, 9 ex
Patients will be taking lorcaserin 10mg tablet by mouth twice daily. In addition, patients will be provided with intensive dietary counseling to promote weight loss.
PURPOSE:To obtain an orally administrable medicine, containing a benzonitrile derivative as an active ingredient and having inhibiting actions on bonding of especially an acidocyte to vascular endothelial cells and excellent suppressing actions on the infiltration of the acidocyte into an inflammatory lesion. CONSTITUTION:This suppressant and antiinflammatory agent for acidocyte infiltration contains a compound of the formula (R<1> is H, a 1-6C lower alkyl or a 2-10C acyl; R<2> is H or a halogen) as an active ingredient. The compound is useful for preventing and treating diseases in which an acidocyte participates, e.g. eczema, pemphigus, pemphigoid, impetigo herpetiformis, psoriasis, chronic obstructive pulmonary diseases, alveolar hypersensitivity, pulmonary aspergillosis, eosinophilic pneumonia, eosinophilic gastroenteritis or colitis ulcerosa. This agent can be formulated as a pharmaceutical preparation by adding a usual medicinal carrier thereto for oral and parenteral administrations according to a conventional method or in the form of an aerosol spray or a dried powder for transpulmonary administration with an aspirator. 3-(Acetoxyacetylamirno)-5- amino-4-chlorobenzonitrile, etc., are exemplified as the compound of the formula.
FIELD: medicine, allergology. SUBSTANCE: lignosulfonate taken on the basis of preliminary experiment data is added to cement or/and cement-containing compositions. Lignosulfonate decreases content of water-soluble Cr 6+  in cement and/or cement-containing composition to value less 0.1 x 10 -3 . This selected lignosulfonate is added to cement and/or cement-containing compositions before or during water addition in preparing fresh cement-containing mixtures. Method decreases allergy by using a substance that retains its properties in dry cement-containing mixtures and showing safety in terms of labor hygiene. EFFECT: decreased allergic response. 11 cl, 4 tbl, 4 ex
Patients receive paclitaxel and carboplatin as in Arm I. Patients also receive placebo PO BID (approximately every 12 hours) on days 2-19.
What is described is a novel genetic screen, involving recombinant technology and class I antigen cross-presentation, to search for supraoptimal superagonists of the 27L MART-1 mutant selecting for single amino acid substitution mutants of 27L that activate human antigen-specific CTL clones recognizing the wild-type MART-1 26-35  epitope. Three novel mutant epitopes are identified with superagonist properties that are functionally superior to 27L. The ability of a given analog to act as superagonist varies among patients. Also described is the use of methods to establish panels of potential superagonist APLs to individualize tumor peptide vaccines among patients. The methodology is replicated to identify APL to NY-ESO-1 157-165  and NY-ESO-1 157-170  tumor epitopes. A general method is described that is useful to produce a tumor vaccine to any tumor epitope.
OBJECTIVE: Parapharyngeal space (PPS) is a rare and unusual site of head and neck squamous cell carcinoma (SCC) metastases. Treatment strategy for PPS metastases is still not well defined. This research aims to investigate the clinical implications and oncological outcomes of SCC metastases in PPS.
MATERIAL AND METHODS: A systematic review was conducted according to PRISMA criteria. The authors considered only articles reporting the history and treatment of patients with PPS SCC metastases. A retrospective chart review was conducted in two tertiary referral academic centers collecting data of patients with diagnosis of PPS SCC metastases between 2010 and 2023 to study their outcome based on clinical presentation and treatment strategy.
RESULTS: The retrospective chart review showed that the oropharynx was the most frequent primary tumour site. The advanced stage at the time of diagnosis was related to poorer survival and higher recurrence rates. A significant difference in 2-year overall survival in the subgroup of patients who experienced PPS metastases within the primary treatment and those who experienced PPS metastases as regional recurrence (66.7 vs 30.8%) was observed. Similar low survival rates were reported in the literature review with a mean overall and disease-free survival of 19.8 and 8.6 months, respectively.
CONCLUSIONS: PPS metastases are associated with a dismal prognosis, especially when diagnosed as regional recurrence after primary treatment, due to patients' poor general conditions and difficulty of treatment.
OBJECTIVE: The purpose of this study was to investigate the current research status, focus areas, and developmental trends in the field of Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) through an analysis of scientific literature.
METHODS: The relevant research articles on MOGAD published from 1947 to 2022 were retrieved from the Web of Science database. The quantitative output of MOGAD related research articles, their distribution by country/region, data on collaborative publishing, influential authors, high-yield institutions, keywords, hotspots, and development trends were analyzed. Additionally, visual knowledge maps were generated using VOSviewer and Citespace.
RESULTS: There has been a steady increase in the number of MOGAD related publications indicating that the subject has garnered increasing interest among researchers globally. The United States has been the leading contributor with 496 papers (19.25%), followed by China (244, 9.63%), Japan (183, 7.10%), the United Kingdom (154, 5.98%), and Germany (149, 5.78%). Among these countries, the United Kingdom boasts the highest citation frequency at the rate of 46.49 times per paper. Furthermore, active collaboration in MOGAD related research is observed primarily between the United States and countries such as Canada, Germany, Australia, Italy, the United Kingdom and Japan. Mayo Clinic ranks first in total articles published (109) and frequency of citations per article (77.79). Takahashi Toshiyuki from Tohoku University is the most prolific author, while Multiple Sclerosis and Related Disorders is the most widely read journal in this field. "Disease Phenotype", "Treatment", "Novel Coronavirus Infection and Vaccination", "Immunopathological Mechanisms", "Clinical characteristics of children" and "Prognosis" are the primary keywords clusters in this field. "Novel Coronavirus Infection and Vaccination" and "Immunopathological Mechanisms" are research hotspots and have great development potential.
CONCLUSION: The past three decades have witnessed a significant expansion of research on MOGAD. The pathogenetic mechanism of MOGAD is poised to be the prominent research focus in this field in the foreseeable future.
BACKGROUND AND AIMS: The transjugular intrahepatic portosystemic shunt has controversial survival benefits; thus, patient screening should be performed preoperatively. In this study, we aimed to develop a model to predict post-transjugular intrahepatic portosystemic shunt mortality to aid clinical decision making.
METHODS: A total of 811 patients undergoing transjugular intrahepatic portosystemic shunt from five hospitals were divided into the training and external validation data sets. A modified prediction model of post-transjugular intrahepatic portosystemic shunt mortality (ModelMT ) was built after performing logistic regression. To verify the improved performance of ModelMT , we compared it with seven previous models, both in discrimination and calibration. Furthermore, patients were stratified into low-, medium-, high- and extremely high-risk subgroups.
RESULTS: ModelMT demonstrated a satisfying predictive efficiency in both discrimination and calibration, with an area under the curve of .875 in the training set and .852 in the validation set. Compared to previous models (ALBI, BILI-PLT, MELD-Na, MOTS, FIPS, MELD, CLIF-C AD), ModelMT showed superior performance in discrimination by statistical difference in the Delong test, net reclassification improvement and integrated discrimination improvement (all p < .050). Similar results were observed in calibration. Low-, medium-, high- and extremely high-risk groups were defined by scores of ≤160, 160-180, 180-200 and >200, respectively. To facilitate future clinical application, we also built an applet for ModelMT .
CONCLUSIONS: We successfully developed a predictive model with improved performance to assist in decision making for transjugular intrahepatic portosystemic shunt according to survival benefits.